Conatus Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.conatuspharma.com
Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT01912404
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 114
- Registration Number
- NCT01273064
- Locations
- 🇺🇸
Liver Center of Atlanta, Atlanta, Georgia, United States
🇺🇸St. Louis University, St. Louis, Missouri, United States
🇺🇸University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States
Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT01051921
- Locations
- 🇺🇸
Henry Ford Medical Center-Columbus, Novi, Michigan, United States
🇺🇸South Denver Gastroenterology, Englewood, Colorado, United States
🇺🇸MN Clinical Research Center, Plymouth, Minnesota, United States
CTS-1027 in Interferon-Naive Hepatitis C Patients
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2009-06-23
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT00925990
- Locations
- 🇺🇸
Henry Ford Medical Center-Columbus, Novi, Michigan, United States
🇺🇸St. Louis University, St. Louis, Missouri, United States
🇺🇸University of MA Mem Med Ctr, Worchester, Massachusetts, United States
Study of CTS-1027 in Hepatitis C Patients
- Conditions
- Chronic Hepatitis C Virus Infection
- Interventions
- Other: Placebo
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT00570336
- Locations
- 🇺🇸
Kaiser Permanente, San Diego, California, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Colorado Denver, Aurora, Colorado, United States
A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
- First Posted Date
- 2004-07-21
- Last Posted Date
- 2012-08-13
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 204
- Registration Number
- NCT00088140
- Locations
- 🇺🇸
Metrohealth Medical Center, Cleveland, Ohio, United States
🇺🇸Mt. Sinai School of Medicine, New York City, New York, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
- Conditions
- Liver TransplantationHepatitisCholestasisCarcinoma, Hepatocellular
- Interventions
- Drug: Placebo
- First Posted Date
- 2004-03-26
- Last Posted Date
- 2012-08-10
- Lead Sponsor
- Conatus Pharmaceuticals Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT00080236
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Mayo Clinic Scottsdale, Phoenix, Arizona, United States
🇺🇸Mount Sinai School of Medicine, New York City, New York, United States